Remedium Bio Raises $10 Million in Series A Funding
Remedium Bio, a company focused on developing innovative gene therapy solutions, has successfully raised $10 million in a Series A funding round. The funding round, announced on August 10, 2026, was led by Lifespan Vision Ventures, with participation from notable investors Eli Lilly and HKX Capital.
Leadership and Vision
The company is spearheaded by Frank Luppino, who serves as President and CEO. Under his leadership, Remedium Bio aims to advance its research and development efforts in the field of gene therapy, targeting unmet medical needs.
Strategic Use of Funds
While specific plans for the newly acquired funds have not been disclosed, it is expected that the investment will be directed towards accelerating the development of Remedium Bio's gene therapy pipeline. This includes potential expansion of research capabilities and strategic hires to bolster their scientific and operational teams.
Location
Remedium Bio is based in Needham, Massachusetts, United States, positioning it strategically within a hub of biotech innovation.
Conclusion
This significant investment marks a pivotal moment for Remedium Bio as it continues to pursue advancements in gene therapy. With the backing of prominent investors, the company is well-positioned to make impactful strides in addressing complex genetic disorders.